LAIR1 and leukemia: Any approach to targeting LAIR1-inhibitory signaling must address the differential effects of LAIR protein expression in cells to be restrained (leukemia/lymphoma, suppressive TAMs) and in cells to be activated (exhausted cytotoxic T cells), as well as the collagen content of the TME, because this also affects LAIR signaling.